This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Vistagen Therapeutics Stock Plummets...
Business stock drop

Vistagen Therapeutics Stock Plummets on Failed Trial

Analysis based on 70 articles · First reported Jan 28, 2026 · Last updated Mar 27, 2026

Sentiment
-20
Attention
2
Articles
70
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The market is negatively impacted by the significant stock price drop of Vistagen Therapeutics, reflecting investor concern over failed clinical trials in the biotechnology sector. This event could lead to increased scrutiny of other small-cap biotech companies and their clinical pipelines.

Biotechnology Pharmaceuticals
Event Summary

Vistagen Therapeutics announced that its PALISADE-3 Public Speaking Challenge Study of fasedienol for social anxiety disorder failed to meet its primary efficacy endpoint. This news led to an over 81% drop in Vistagen Therapeutics' stock price, opening at $0.88 per share. Faruqi & Faruqi, a securities litigation firm, is now encouraging investors who suffered losses to contact them, suggesting potential legal action against Vistagen Therapeutics.

Key Actions
100 Vistagen Therapeutics announced failed Phase 3 clinical trial results for fasedienol
100 Vistagen Therapeutics announced failed clinical trial results
95 Vistagen Therapeutics stock price fell over 80%
95 Vistagen Therapeutics stock price fell over 81%
90 Faruqi & Faruqi investigating potential claims and filing a class action lawsuit Vistagen Therapeutics
90 Faruqi & Faruqi investigating potential claims Vistagen Therapeutics
90 Faruqi & Faruqi filed federal securities class action Vistagen Therapeutics
40 Faruqi & Faruqi encouraged investors to contact them Vistagen Therapeutics
Entities Involved
stock
Vistagen Therapeutics
Vistagen Therapeutics' stock price fell over 81% after its PALISADE-3 study for fasedienol failed to meet its primary efficacy endpoint, indicating a significant setback for the company.
Importance 100 Sentiment -90
stock
Zynex
Zynex is facing a federal securities class action lawsuit for allegedly inflating revenue through excessive product shipments and fraudulent overbilling, leading to scrutiny from insurers like United States===Tricare and a lawsuit from The Travelers Companies. This has resulted in significant stock price declines and leadership changes.
Importance 100 Sentiment -90
per
Thomas Sandgaard
Thomas Sandgaard, the former CEO of Zynex, is named in The Travelers Companies' lawsuit for his alleged involvement in a fraudulent overbilling scheme and was replaced as CEO.
Importance 90 Sentiment -80
govactor
United States===Tricare
United States===Tricare, the health insurance program for the U.S. military and Zynex's largest customer, temporarily suspended payments to Zynex due to a review of prior claims, significantly impacting Zynex's revenue.
Importance 80 Sentiment 0
priv
Faruqi & Faruqi
Faruqi & Faruqi, a national securities law firm, is investigating Vistagen Therapeutics for potential securities law violations and is encouraging investors to join a class action lawsuit. This event enhances the firm's visibility and potential for new clients.
Importance 70 Sentiment 10
per
James Wilson (lawyer)
James Wilson (lawyer), a partner at Faruqi & Faruqi, is actively encouraging investors who suffered losses in Vistagen Therapeutics to contact him directly to discuss their legal options. His involvement highlights his role in the securities litigation.
Importance 60 Sentiment 10
stock
The Travelers Companies
The Travelers Companies commenced an action against Zynex and its executives, alleging a fraudulent overbilling scheme and seeking more than $23 million in damages and civil penalties.
Importance 60 Sentiment 0
+ 3 more entities View on Dashboard
Relationships
James Wilson (lawyer) related ↔ Faruqi & Faruqi
Faruqi & Faruqi related ↔ Vistagen Therapeutics
Faruqi & Faruqi related ↔ Zynex
United States===Tricare related ↔ Zynex
The Travelers Companies related ↔ Zynex
Steven Dyson related ↔ Zynex
Daniel Moorhead related ↔ Zynex
Thomas Sandgaard related ↔ Zynex
Faruqi & Faruqi related ↔ United States===Tricare
Thomas Sandgaard related ↔ Faruqi & Faruqi
+ 3 more relationships View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.